Literature DB >> 16467624

Intraoperative electron radiotherapy for extremity sarcomas does not increase acute or late morbidity.

Charles Kunos1, Valdir Colussi, Patrick Getty, Timothy Kinsella.   

Abstract

UNLABELLED: Intraoperative electron radiotherapy is used to treat surgical sites that potentially harbor occult tumor immediately after limb-sparing surgical resection of extremity soft tissue sarcomas. It is unknown whether single-fraction, high-dose intraoperative electron radiotherapy at the time of surgery increases wound morbidity when combined with preoperative or postoperative external beam radiotherapy. In a retrospective study, we evaluated whether intraoperative electron radiotherapy increased 90-day and late (> 90 days) wound complication rates by comparing patients who had adult extremity soft tissue sarcomas treated by limb-sparing surgery and preoperative (n = 14) or postoperative (n = 13) external beam radiotherapy. The median followup was 36 months. Seven (26%) patients had wound complications occurring within 90 days postoperatively and completion of radiotherapy. Late wound complication rates were similar. Two patients in each of the external beam radiotherapy groups required late subtotal limb amputations for prolonged wound complications. Our findings suggest intraoperative electron radiotherapy during limb-sparing surgery allows radiation dose escalation without increased 90-day or late-wound complication rates when combined with preoperative or postoperative external beam radiotherapy for patients with extremity soft tissue sarcomas. LEVEL OF EVIDENCE: Prognostic Study, Level II (retrospective study). See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2006        PMID: 16467624     DOI: 10.1097/01.blo.0000203470.43184.8c

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

1.  Risk factors for significant wound complications following wide resection of extremity soft tissue sarcomas.

Authors:  Adam Schwartz; Alanna Rebecca; Anthony Smith; William Casey; Jonathan Ashman; Leonard Gunderson; Kelly Curtis; Yu-Hui H Chang; Christopher Beauchamp
Journal:  Clin Orthop Relat Res       Date:  2013-06-28       Impact factor: 4.176

2.  Commissioning, clinical implementation, and performance of the Mobetron 2000 for intraoperative radiation therapy.

Authors:  Landon S Wootton; Juergen Meyer; Edward Kim; Mark Phillips
Journal:  J Appl Clin Med Phys       Date:  2017-01       Impact factor: 2.102

Review 3.  Intraoperative radiation therapy (IORT) in soft-tissue sarcoma.

Authors:  Falk Roeder; Robert Krempien
Journal:  Radiat Oncol       Date:  2017-01-19       Impact factor: 3.481

4.  Radiation therapy in addition to gross total resection of retroperitoneal sarcoma results in prolonged survival: results from a single institutional study.

Authors:  Timothy M Zagar; Robert R Shenk; Julian A Kim; Deb Harpp; Charles A Kunos; Fadi W Abdul-Karim; William C Chen; Yuji Seo; Timothy J Kinsella
Journal:  J Oncol       Date:  2009-01-29       Impact factor: 4.375

5.  Intraoperative radiotherapy (IORT) combined with external beam radiotherapy (EBRT) for soft-tissue sarcomas--a retrospective evaluation of the Homburg experience in the years 1995-2007.

Authors:  Marcus Niewald; Jochen Fleckenstein; Norbert Licht; Caroline Bleuzen; Christian Ruebe
Journal:  Radiat Oncol       Date:  2009-08-26       Impact factor: 3.481

6.  Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.

Authors:  Falk Roeder; Burkhard Lehner; Thomas Schmitt; Bernd Kasper; Gerlinde Egerer; Oliver Sedlaczek; Carsten Grüllich; Gunhild Mechtersheimer; Patrick Wuchter; Frank W Hensley; Peter E Huber; Juergen Debus; Marc Bischof
Journal:  BMC Cancer       Date:  2014-05-20       Impact factor: 4.430

Review 7.  Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents.

Authors:  Cameron M Callaghan; M M Hasibuzzaman; Samuel N Rodman; Jessica E Goetz; Kranti A Mapuskar; Michael S Petronek; Emily J Steinbach; Benjamin J Miller; Casey F Pulliam; Mitchell C Coleman; Varun V Monga; Mohammed M Milhem; Douglas R Spitz; Bryan G Allen
Journal:  Cancers (Basel)       Date:  2020-08-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.